NCT07011719Phase 3Recruiting

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Study sponsor: Arcus Biosciences, Inc. · RCUS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-04Estimated
Enrollment · participants720Estimated
Source updated2026-11-02Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview